Eli Lilly | LLY - Bienes





Bienes Cambio Fecha
AbbVie USD 135.12B 1.35B 2026-06
Abbott USD 110.43B 23.72B 2026-03
ALKERMES USD 4.39B 135.05M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Baxter International USD 19.41B 377M 2026-09
Biogen USD 32.05B 32.5M 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Coherus Biosciences USD 191.18M 74.84M 2026-06
Drreddys Laboratories INR 579.35B 573.08B 2026-03
Eli Lilly USD 148.07B 5.79B 2026-09
Gilead Sciences USD 51.41B 2.05B 2026-09
GlaxoSmithKline GBP 71.7B 9.96B 2026-09
Glaxosmithkline GBP 62.87B 19.47B 2026-03
J&J USD 197.42B 3.64B 2026-09
Medtronic USD 93.31B 278M 2026-06
Merck USD 129.8B 1.12B 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novartis USD 118.53B 7.58B 2026-03
Novo Nordisk DKK 594.94B 35.72B 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Phibro Animal Health USD 1.5B 56.12M 2026-06
Prestige Brands USD 4.57B 1.07B 2026-06
Regeneron Pharmaceuticals USD 44.41B 2.67B 2026-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Sanofi EUR 128.02B 1.22B 2026-03
United Therapeutics USD 7.22B 505.9M 2026-06
Zoetis USD 15.08B 77M 2026-06